Huntington disease (HD) is an inherited neurodegenerative disease that affects multiple brain regions. It is caused by an expanded polyglutamine tract in huntingtin (Htt). The development of therapies for HD and other neurodegenerative diseases has been hampered by multiple factors, including the lack of clear therapeutic targets, and the cost and complexity of testing lead compounds in vivo. The R6/2 HD mouse model is widely used for pre-clinical trials because of its progressive and robust neural dysfunction, which includes retinal degeneration. Profilin-1 is a Htt binding protein that inhibits Htt aggregation. Its binding to Htt is regulated by the rho-associated kinase (ROCK), which phosphorylates profilin at Ser-137. ROCK is thus a therapeutic target in HD. The ROCK inhibitor Y-27632 reduces Htt toxicity in fly and mouse models. Here we characterized the progressive retinopathy of R6/2 mice between 6–19 weeks of age to determine an optimal treatment window. We then tested a clinically approved ROCK inhibitor, HA-1077, administered intravitreally via liposome-mediated drug delivery. HA-1077 increased photopic and flicker ERG response amplitudes in R6/2 mice, but not in wild-type littermate controls. By targeting ROCK with a new inhibitor, and testing its effects in a novel in vivo model, these results validate the in vivo efficacy of a therapeutic candidate, and establish the feasibility of using the retina as a readout for CNS function in models of neurodegenerative disease.
References
[1]
The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971–983.
[2]
Mangiarini L, Kirupa S, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493–506.
[3]
Helmlinger D, Yvert G, Picaud S, Merienne K, Sahel J, et al. (2002) Progressive retinal degeneration and dysfunction in R6 Huntington's disease mice. Hum Mol Genet 11: 3351–3359.
[4]
Petrasch-Parwez E, Habbes HW, Weickert S, Lobbecke-Schumacher M, Striedinger K, et al. (2004) Fine-structural analysis and connexin expression in the retina of a transgenic model of Huntington's disease. J Comp Neurol 479: 181–197.
[5]
Batcha AH, Greferath U, Jobling AI, Vessey KA, Ward MM, et al. (2012) Retinal dysfunction, photoreceptor protein dysregulation and neuronal remodelling in the R6/1 mouse model of Huntington's disease. Neurobiol Dis 45: 887–896.
[6]
Li M, Huang Y, Ma AA, Lin E, Diamond MI (2009) Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol Dis 36: 413–420.
[7]
Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, et al. (2003) A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40: 685–694.
[8]
Shao J, Welch WJ, Diprospero NA, Diamond MI (2008) Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol 28: 5196–5208.
[9]
Hanada Y, Kudo H, Kohmura E (2005) Chronologic changes of fasudil hydrochloride and hydroxyfasudil in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 14: 47–49.
[10]
Bayer AU, Mittag T, Cook P, Brodie SE, Podos SM, et al. (1999) Comparisons of the amplitude size and the reproducity of three different electrodes to record the corneal flash electroretinogram in rodents. Doc Ophthalmol 98: 233–246.
[11]
McGill TJ, Prusky GT, Douglas RM, Yasumura D, Matthes MT, et al. (2007) Intraocular CNTF reduces vision in normal rats in a dose-dependent manner. Invest Ophthalmol Vis Sci 48: 5756–5766.
[12]
LaVail MM, Battelle BA (1975) Influence of eye pigmentation and light deprivation on inherited retinal dystrophy in the rat. Exp Eye Res 21: 167–192.
[13]
LaVail MM, Gorrin GM, Repaci MA, Thomas LA, Ginsberg HM (1987) Genetic regulation of light damage to photoreceptors. Invest Ophthalmol Vis Sci 28: 1043–1048.
[14]
Carter-Dawson LD, LaVail MM, Sidman RL (1978) Differential effect of the rd mutation on rods and cones in the mouse retina. Invest Ophthalmol Vis Sci 17: 489–498.
[15]
LaVail MM, Matthes MT, Yasumura D, Steinberg RH (1997) Variability in rate of cone degeneration in the retinal degeneration (rd/rd) mouse. Exp Eye Res 65: 45–50.
[16]
Ishida T, Takanashi Y, Doi H, Yamamoto I, Kiwada H (2002) Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes. Int J Pharm 232: 59–67.
[17]
Mattapallil MJ, Wawrousek EF, Chan CC, Zhao H, Roychoudhury J, et al. (2012) The Rd8 mutation of the Crb1 Gene Is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotyping. Invest Ophthalmol Vis Sci 53: 2921–2927.
[18]
Michon JJ, Li ZL, Shioura N, Anderson RJ, Tso MOM (1991) A comparative study of methods of photoreceptor morphometry. Invest Ophthalmol Vis Sci 32: 280–284.
[19]
Carter-Dawson LD, LaVail MM (1979) Rods and cones in the mouse retina. I. Structural analysis using light and electron microscopy. J Comp Neur 188: 245–262.
[20]
LaVail MM, Blanks JC, Mullen RJ (1982) Retinal degeneration in the pcd cerebellar mutant mouse. I. Light microscopic and autoradiographic analysis. J Comp Neur 212: 217–230.
[21]
LaVail MM, White MP, Gorrin GM, Porrello KV, Mullen RJ (1993) Retinal degeneration in the nervous mutant mouse. I. Light microscopic cytopathology and changes in the interphotoreceptor matrix. J Comp Neur 333: 168–181.
[22]
Masaoka H, Takasato Y, Nojiri T, Hayakawa T, Akimoto H, et al. (2001) Clinical effect of Fasudil hydrochloride for cerebral vasospasm following subarachnoid hemorrhage. Acta Neurochir Suppl 77: 209–211.
[23]
Nakashima S, Tabuchi K, Shimokawa S, Fukuyama K, Mineta T, et al. (1998) Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 38: 805–810 discussion 810-801.
[24]
Szoka F Jr, Papahadjopoulos D (1978) Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A 75: 4194–4198.
[25]
Barza M, Stuart M, Szoka F Jr (1987) Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci 28: 893–900.
[26]
Ishida T, Takanashi Y, Kiwada H (2006) Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biol Pharm Bull 29: 397–402.
[27]
Tremblay C, Barza M, Szoka F, Lahav M, Baum J (1985) Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits. Invest Ophthalmol Vis Sci 26: 711–718.
[28]
Lewin AS, Drenser KA, Hauswirth WW, Nishikawa S, Yasumura D, et al. (1998) Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nature Med 4: 967–971.
[29]
Paskowitz DM, Nune G, Yasumura D, Yang H, Bhisitkul RB, et al. (2004) BDNF reduces the retinal toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci 45: 4190–4196.
[30]
Mocko JA, Kim M, Faulkner AE, Cao Y, Ciavatta VT, et al. (2011) Effects of subretinal electrical stimulation in mer-KO mice. Invest Ophthalmol Vis Sci 52: 4223–4230.
[31]
La Spada AR, Fu YH, Sopher BL, Libby RT, Wang X, et al. (2001) Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31: 913–927.
[32]
Yefimova MG, Messaddeq N, Karam A, Jacquard C, Weber C, et al. (2010) Polyglutamine toxicity induces rod photoreceptor division, morphological transformation or death in spinocerebellar ataxia 7 mouse retina. Neurobiol Dis 40: 311–324.
[33]
Yoo SY, Pennesi ME, Weeber EJ, Xu B, Atkinson R, et al. (2003) SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37: 383–401.
[34]
Yvert G, Lindenberg KS, Picaud S, Landwehrmeyer GB, Sahel JA, et al. (2000) Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet 9: 2491–2506.
[35]
Helmlinger D, Abou-Sleymane G, Yvert G, Rousseau S, Weber C, et al. (2004) Disease progression despite early loss of polyglutamine protein expression in SCA7 mouse model. J Neurosci 24: 1881–1887.
[36]
Abou-Sleymane G, Chalmel F, Helmlinger D, Lardenois A, Thibault C, et al. (2006) Polyglutamine expansion causes neurodegeneration by altering the neuronal differentiation program. Hum Mol Genet 15: 691–703.
[37]
Leveillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, et al. (2004) Identification and characterization of rod-derived cone viability factor. Nat Genet 36: 755–759.
[38]
Pang JJ, Deng WT, Dai X, Lei B, Everhart D, et al. (2012) AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One 7: e35250.
[39]
Bauer PO, Nukina N (2009) Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy. Autophagy 5: 747–748.
[40]
Bauer PO, Wong HK, Oyama F, Goswami A, Okuno M, et al. (2009) Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J Biol Chem 284: 13153–13164.
[41]
Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boontheung P, et al. (2012) Network organization of the huntingtin proteomic interactome in Mammalian brain. Neuron 75: 41–57.
[42]
Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 6182–6195.
